Patents by Inventor Gustave Bergnes

Gustave Bergnes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230365556
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 16, 2023
    Applicant: Pliant Therapeutics, Inc.
    Inventors: Lan JIANG, David John MORGANS, JR., Gustave BERGNES, Chun CHEN, Hui LI, Patrick ANDRE, Randall L. HALCOMB, Jacob CHA, Timothy HOM
  • Patent number: 11673887
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: June 13, 2023
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Lan Jiang, David John Morgans, Jr., Gustave Bergnes, Chun Chen, Hui Li, Patrick Andre, Randall Halcomb, Jacob Cha, Timothy Hom
  • Patent number: 11634418
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: April 25, 2023
    Assignee: Pliant Therapeutics, Inc.
    Inventors: David John Morgans, Jr., Randall L. Halcomb, Gustave Bergnes, Hui Li, Lan Jiang, Jacob Cha, Timothy Hom
  • Publication number: 20230026651
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 20, 2022
    Publication date: January 26, 2023
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • Patent number: 11369565
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: June 28, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Publication number: 20210122747
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, R5, R7, R8. X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: June 5, 2020
    Publication date: April 29, 2021
    Inventors: David John MORGANS, Jr., Randall L. HALCOMB, Gustave BERGNES, Hui LI, Lan JIANG, Jacob CHA, Timothy HOM
  • Publication number: 20210045997
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: February 18, 2021
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • Publication number: 20210024516
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Application
    Filed: March 4, 2020
    Publication date: January 28, 2021
    Inventors: Lan JIANG, David John MORGANS, Jr., Gustave BERGNES, Chun CHEN, Hui LI, Patrick ANDRE, Randall HALCOMB, Jacob CHA, Timothy HOM
  • Patent number: 10765624
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 8, 2020
    Assignee: CYTOKINETICS, INC.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Patent number: 10696672
    Abstract: The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 30, 2020
    Assignee: Pliant Therapeutics, Inc.
    Inventors: David John Morgans, Jr., Randall L. Halcomb, Gustave Bergnes, Hui Li, Lan Jiang, Jacob Cha, Timothy Hom
  • Patent number: 10604520
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 31, 2020
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Lan Jiang, David John Morgans, Jr., Gustave Bergnes, Chun Chen, Hui Li, Patrick Andre, Randall L. Halcomb, Jacob Cha, Timothy Hom
  • Publication number: 20190322663
    Abstract: The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: December 20, 2017
    Publication date: October 24, 2019
    Inventors: David John MORGANS, Jr., Randall L. HALCOMB, Gustave BERGNES, Hui LI, Lan JIANG, Jacob CHA, Timothy HOM
  • Publication number: 20190307677
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 13, 2019
    Publication date: October 10, 2019
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • Patent number: 10272030
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 30, 2019
    Assignee: Cytokinetics, Inc.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Patent number: 10076519
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: September 18, 2018
    Assignee: CYTOKINETICS, INC.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R. Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang, Pu-Ping Lu, Antonio Romero
  • Patent number: 9994528
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: June 12, 2018
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R Muci, Xiangping Qian, Antonio Romero, Jeffrey Warrington, Zhe Yang
  • Publication number: 20180093984
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Application
    Filed: September 7, 2017
    Publication date: April 5, 2018
    Inventors: Lan JIANG, David John MORGANS, JR., Gustave BERGNES, Chun CHEN, Hui LI, Patrick ANDRE, Randall L. HALCOMB, Jacob CHA, Timothy HOM
  • Publication number: 20180064637
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 10, 2017
    Publication date: March 8, 2018
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • Publication number: 20170281621
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 20, 2017
    Publication date: October 5, 2017
    Inventors: Luke W. ASHCRAFT, Gustave BERGNES, Scott COLLIBEE, Chihyuan CHUANG, Jeff GARDINA, Bradley P. MORGAN, Alex R. MUCI, Xiangping QIAN, Jeffrey WARRINGTON, Zhe YANG, Pu-Ping LU, Antonio ROMERO
  • Patent number: 9730886
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: August 15, 2017
    Assignee: Cytokinetics, Inc.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu